Loading stock data…
GMAB
$25.10+0.30 (+1.21%)
After Hours$25.10+0.00 (+0.00%)· Last close Jun 9
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genmab A/S in the Healthcare sector is trading at $25.10. Wall Street consensus targets $36.82 (11 analysts), implying a +46.7% move over the next 12 months. The stock is currently 29% below its 52-week high of $35.43, remaining 14.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +46.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$25.10
Potential Downside
0%
Whystock Fair Value$25.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$36.82+46.7%
Range$32.00 – $41.50
Fundamentals
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.45%
Volume
Today's trading volume
1.32M
Recent News
Truist Assigns Buy Rating to Genmab (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential. On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza. The analyst reduced the price target from $48 to $40 and assigned a Buy rating to the stock. He shared an optimistic […]
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate
Recent performance snapshot Genmab (CPSE:GMAB) has seen mixed share price moves recently, with the stock down about 1.7% on the day and lower over the past month and past 3 months, but higher over the past year. For context, Genmab reports revenue of 3,901 million DKK and net income of 821 million DKK from its antibody focused biotechnology business, and currently carries a market value of about 103.4b DKK. See our latest analysis for Genmab. At the current share price of DKK1,684.0, Genmab’s...
Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares. On May 7, Genmab A/S (NASDAQ:GMAB) reported revenue of $896 million for Q1 2026, […]
Junk-Rated Firms Rush to Reprice Risky Debt as Demand Surges
(Bloomberg) -- Junk-rated firms are rushing to reprice and refinance debt, seizing on renewed investor appetite for riskier US dollar-denominated loans to slash borrowing costs. Most Read from BloombergAmbani’s Cola War With Coke, Pepsi Spurs Fridge Bonanza in IndiaInside a Year of Chaos and Conflict at Kevin Hart’s Media CompanyIran Makes New Offer on Uranium in Response to US, WSJ SaysMamdani Scraps Property Tax Hike, Counts Second-Home RevenueMore than 20 companies have kicked off deals to cu
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance
Wondering whether Genmab stock still offers value at current levels, or if the best of the opportunity is already behind it, starts with understanding what the recent price moves really say about expectations. Over the last week the stock is up 4.1%, while the 1 year return sits at 36.3%. This is even though the year to date return is a 12.4% decline and the 3 and 5 year returns are 38.7% and 21.2% declines respectively. These mixed returns have kept attention on Genmab, with recent coverage...